Universität zu Köln

Journal Article

Abdulla, D. S. Y., Nogova, L., Riedel, R., Scheftler, M., Fischer, R. N., Michels, S., Heydt, C., Ihle, M. A., Fassunke, J., Merkelbach-Bruse, S., Buettner, R. and Wolf, J. (2018). NTRK1/2/3 gene rearrangements define a new and clinically actionable molecular subset of oncogene-driven cancers. Oncol. Res. Treat., 41. S. 293 - 294. BASEL: KARGER. ISSN 2296-5262

Alidousty, C., Baar, T., Martelotto, L. G., Heydt, C., Wagener, S., Fassunke, J., Duerbaum, N., Scheel, A., Frank, S., Holz, B., Binot, E., Kron, A., Merkelbach-Bruse, S., Ihle, M., Wolf, J., Buettner, R. and Schultheis, A. M. (2018). Genetic instability and recurrent MYC amplification in ALK-translocated NSCLC; a central role of TP53 mutations. Virchows Arch., 473. S. S315 - 1. NEW YORK: SPRINGER. ISSN 1432-2307

Ball, M., Fassunke, J., Heydt, C., Fischer, J., Schallenberg, S., Joehrens, K. and Merkelbach-Bruse, S. (2020). External quality assessment of immunohistochemistry, in-situ hybridization and RNA/DNA sequencing for ROS1 testing reveals high concordance for all methods. Ann. Oncol., 31. S. S890 - 1. AMSTERDAM: ELSEVIER. ISSN 1569-8041

Dahl, E., Jung, A., Fassunke, J., Hummel, M., Penzel, R., Dietmaier, W. and Lassmann, S. (2015). Chances and Risks of blood-based molecular pathological Analysis of circulating Tumor Cells (CTC) and cell free DNA (cfDNA) in personalized Cancer Therapy A Statement of the Working Group Liquid Biopsy of the AG Molecular Pathology ini the German Society for Pathology (DGP). Pathologe, 36 (1). S. 92 - 98. HEIDELBERG: SPRINGER HEIDELBERG. ISSN 1432-1963

Hagmeyer, L., Schaefer, S., Fassunke, J., Pietzke-Calcagnile, A., Treml, M., Herkenrath, S. D., Buettner, R. and Randerath, W. J. (2020). Molecular Pathological Analysis in Patients with central Lung Cancer - Endobronchial Ultrasound-guided transbronchial Needle Aspiration and Analysis of circulating Tumor-DNA compared to endobronchial Forceps Biopsy. Pneumologie, 74. S. S129 - 1. STUTTGART: GEORG THIEME VERLAG KG. ISSN 1438-8790

Heydt, C., Baar, T., Wagener, S., Ihle, M. A., Carl, C., Fassunke, J., Buettner, R. and Merkelbach-Bruse, S. (2017). Comparison of custom designed gene panels for hybrid capture-based parallel sequencing in molecular pathology routine diagnostics. J. Mol. Diagn., 19 (2). S. S50 - 2. NEW YORK: ELSEVIER SCIENCE INC. ISSN 1943-7811

Heydt, C., Pappesch, R., Rehker, J., Wagener, S., Ihle, M. A., Siemanowski, J., Buettner, R., Fassunke, J. and Merkelbach-Bruse, S. (2018). Comparison of DNA- and RNA-based parallel sequencing approaches for the detection of MET Exon 14 skipping mutations. Virchows Arch., 473. S. S288 - 1. NEW YORK: SPRINGER. ISSN 1432-2307

Koitzsch, U., Heydt, C., Divakar, K., Attig, H., Fassunke, J., Merkelbach-Bruse, S., Fammartino, A. Alessandro, Buettner, R., Kong, Y. and Odenthal, M. (2017). Analysis of Clinical Relevant Mutations by the Novel Gene Reader NGS System. J. Mol. Diagn., 19 (2). S. S55 - 1. NEW YORK: ELSEVIER SCIENCE INC. ISSN 1943-7811

Kostenko, A., Kron, F., Michels, S., Fassunke, J., Scheffler, M., Sueptitz, J., Fischer, R., DeMary, P., Glossmann, J. P., Buettner, R. and Wolf, J. (2016). The Network Genomic Medicine first joint cost-effectiveness and outcome evaluation based on multiplex lung cancer genotyping. Oncol. Res. Treat., 39. S. 121 - 122. BASEL: KARGER. ISSN 2296-5262

Kostenko, A., Michels, S., Kron, F., Brandes, V, Fischer, R., Nogova, L., Scheffler, M., Fassunke, J., Merkelbach-Bruse, S., Scheel, A., Ueckeroth, F., Sueptitz, J., Gerigk, M., Heydt, C., Glossmann, J. -P, Buettner, R. and Wolf, J. (2016). Improved overall survival following implementation of next generation sequencing in routine diagnostics of advanced lung cancer in Germany: results of the Network Genomic Medicine. Oncol. Res. Treat., 39. S. 305 - 307. BASEL: KARGER. ISSN 2296-5262

Kron, A., Alidousty, C., Scheffler, M., Merkelbach-Bruse, S., Seidel, D., Riedel, R., Ihle, M. A., Michels, S., Nogova, L., Fassunke, J., Heydt, C., Kron, F., Ueckeroth, F., Serke, M., Krueger, S. ORCID: 0000-0002-1658-5993, Grohe, C., Koschel, D., Benedikter, J., Kaminsky, B., Schaaf, B., Braess, J., Sebastian, M., Kambartel, K. -O., Thomas, R., Zander, T., Schultheis, A. M., Buettner, R. and Wolf, J. (2018). Impact of TP53 mutation status on systemic treatment outcome in ALK-rearranged non-small-cell lung cancer. Ann. Oncol., 29 (10). S. 2068 - 2076. OXFORD: OXFORD UNIV PRESS. ISSN 1569-8041

Kron, A., Riedel, R., Michels, S., Fassunke, J., Merkelbach-Bruse, S., Scheffler, M., Nogova, L., Fischer, R., Ueckeroth, F., Abdulla, D., Kron, F., Pauli, B., Kaminsky, B., Braess, J., Graeven, U., Grohe, C., Krueger, S. ORCID: 0000-0002-1658-5993, Buettner, R. and Wolf, J. (2017). Impact of co-occurring genomic alterations on overall survival of BRAF V600E and non-V600E mutated NSCLC patients: Results of the Network Genomic Medicine. Ann. Oncol., 28. OXFORD: OXFORD UNIV PRESS. ISSN 1569-8041

Kron, A., Riedel, R., Michels, S., Fassunke, J., Merkelbach-Bruse, S., Scheffler, M., Ueckeroth, F., Schueller, M., Pauli, B., Grohe, C., Kaminsky, B., Braess, J., Graeven, U., Krueger, S., Nogova, L., Abdulla, D., Fischer, R., Heydt, C., Buettner, R. and Wolf, J. (2017). Impact of co-occurring genomic alterations on overall survival of BRAF mutated lung cancer patients: results of the Network Genomic Medicine. Oncol. Res. Treat., 40. S. 247 - 248. BASEL: KARGER. ISSN 2296-5262

Kron, A., Riedel, R., Michels, S., Heydt, C., Fassunke, J., Merkelbach-Bruse, S., Scheffler, M., Fischer, R., Abdulla, D., Nogova, L., Ueckeroth, F., Pauli, B., Schueller, M., Serke, M., Koschel, D., Krueger, S., Grohe, C., Kambartel, K., Sebastian, M., Zander, T., Buettner, R. and Wolf, J. (2017). Impact of next generation tyrosine kinase inhibitors (TKI) and co-occurring mutations in ALK-positive NSCLC patients: results of the Network Genomic Medicine. Oncol. Res. Treat., 40. S. 219 - 220. BASEL: KARGER. ISSN 2296-5262

Michels, S., Heydt, C., Deschler-Baier, B., Ruesseler, V., Stratmann, J., Steinhauser, S., Fischer, R., Scheffler, M., Fassunke, J., Kron, A., Griesinger, F., Gautschi, O., Sebastian, M., Hellmich, M., Heukamp, L., Merkelbach-Bruse, S., Bttner, R. and Wolf, J. (2017). Molecular panel sequencing of pre-treatment samples reveals mechanisms of innate resistance to 3rd generation EGFR TKI treatment in T790M-positive NSCLC patients. Oncol. Res. Treat., 40. S. 134 - 135. BASEL: KARGER. ISSN 2296-5262

Michels, S., Westphal, T., Nogova, L., Scheffler, M., Deschler-Baier, B., Sebastian, M., Schuler, M., Wermke, M., Abdulla, D. S. Y., Fischer, R. N., Koleczko, S., Kron, A., Pinto, A., Riedel, R., Weber, J. -P., Fassunke, J., Merkelbach-Bruse, S., Haverkamp, H., Hellmich, M., Buettner, R. and Wolf, J. (2020). EATON: A phase I dose-escalation trial of nazartinib (EGF816) and trametinib in EGFR-mutant non-small cell lung cancer (NSCLC) - preliminary data. Oncol. Res. Treat., 43 (SUPPL 4). S. 148 - 149. BASEL: KARGER. ISSN 2296-5262

Pasternack, H., Fassunke, J., Plum, P., Chon, S., Merkelbach-Bruse, S., Bruns, C., Perner, S., Hallek, M., Buttner, R., Zander, T., Quaas, A., Weiss, J. and Alakus, H. (2017). Detection of Somatic Alterations in Circulating Cell-free DNA of Esophageal Carcinoma Patients during Primary Staging is Predictive for Post-surgical Tumor Recurrence. J. Mol. Diagn., 19 (2). S. S37 - 2. NEW YORK: ELSEVIER SCIENCE INC. ISSN 1943-7811

Riedel, R., Kron, A., Michels, S., Fassunke, J., Scheffler, M., Fischer, R., Nogova, L., Abdulla, D., Heydt, C., Ueckeroth, F., Pauli, B., Serke, M., Krueger, S. ORCID: 0000-0002-1658-5993, Grohe, C., Sebastian, M., Koschel, D., Kambartel, K-O., Zander, T., Buettner, R. and Wolf, J. (2017). Impact of next generation TKI and co-occurring mutations in ALK-positive NSCLC patients: Results of the Network Genomic Medicine. Ann. Oncol., 28. OXFORD: OXFORD UNIV PRESS. ISSN 1569-8041

Rosswog, C., Fassunke, J., Schoemig-Markiefka, B., Merkelbach-Bruse, S., Ackermann, S., Ortmann, M., Schulte, J., Westermann, F., Berthold, F., Simon, T., Hero, B. and Fischer, M. (2020). ALK Mutations in Primary and Relapsed Neuroblastoma in a GPOH Cohort. Pediatr. Blood Cancer, 67. S. S57 - 2. HOBOKEN: WILEY. ISSN 1545-5017

Scheffler, M., Gardizi, M., Bos, M., Koenig, K., Michels, S., Fassunke, J., Heydt, C., Kuenstlinger, H., Ihle, M. A., Ueckeroth, F., Albus, K., Serke, M., Gerigk, U., Schulte, W., Toepelt, K., Nogova, L., Zander, T., Engel-Riedel, W., Stoelben, E., Ko, Y. -D., Randerath, W. J., Kaminsky, B., Panse, J., Becker, C., Hellmich, M., Merkelbach-Bruse, S., Buettner, R., Heukamp, L. C. and Wolf, J. (2014). Genetic heterogeneity and lack of prognostic impact of patients with non-small cell lung cancer (NSCLC) harboring PIK3CA mutation. Oncol. Res. Treat., 37. S. 65 - 66. BASEL: KARGER. ISSN 2296-5262

Scheffler, M., Nogova, L., Michels, S., Holzem, A., Chanra, T., Abdulla, D. S. Y., Koleczko, S., Merkelbach-Bruse, S., Fassunke, J., Kron, A., Scheel, A. H., Ihle, M. A., Heydt, C., Westphal, T., Weber, J. -P., Fischer, R. N., Riedel, R., Kaminsky, B., Draube, A., Rothe, A., Kambartel, K. -O., Hillmer, A., Buettner, R. and Wolf, J. (2020). KRAS mutations in never-smoker NSCLC patients: Defining a new patient subgroup. Oncol. Res. Treat., 43 (SUPPL 4). S. 139 - 140. BASEL: KARGER. ISSN 2296-5262

Wagener, S., Heydt, C., Fassunke, J., Ihle, M. A., Carl, C., Buttner, R. and Merkelbach-Bruse, S. (2017). Specific and Reliable Detection of NTRK Rearrangements in IHC-Positive FFPE Samples of Solid Tumours by Nanostring Technology. J. Mol. Diagn., 19 (2). S. S33 - 2. NEW YORK: ELSEVIER SCIENCE INC. ISSN 1943-7811

Wagener, S., Ihle, M. A., Alidousty, C., Heydt, C., Fassunke, J., Merkelbach-Bruse, S. and Buettner, R. (2018). The potential biomarkerHR23b regulates sensitivity towards histone deacetylase inhibitors (HDACi) via the NGFR death receptor pathway. Virchows Arch., 473. S. S1 - 1. NEW YORK: SPRINGER. ISSN 1432-2307